RxDoctor Payments Data

Rachel York, APRN

Family · Toledo, OHNPI 1194203539

Payments from drug & device makers

$7,595in general payments, 2019–2025

Across 403 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$847
  • AbbVie$696
  • Boehringer Ingelheim$559
  • Bayer$521
  • Pfizer$501
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$7,595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,595 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$14,515
Medicare patients
67
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide94$98,809
FarxigaDapagliflozin Propanediol66$79,560
OzempicSemaglutide63$78,066
JardianceEmpagliflozin62$56,260
JanuviaSitagliptin Phosphate54$49,701
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$13,856
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,409
Breo ElliptaFluticasone/Vilanterol15$7,758
Tresiba Flextouch U-100Insulin Degludec14$6,994
Atorvastatin Calcium422$4,215
Albuterol Sulfate HfaAlbuterol Sulfate97$2,286
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,243
Metformin Hcl ErMetformin Hcl91$1,798
Fluoxetine Hcl25$1,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$442$98,80994 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,637$89,45180 claims
Novo NordiskOzempic$847$78,06663 claims
Boehringer IngelheimJardiance$559$56,26062 claims
MerckJanuvia$334$49,70154 claims
GSKTrelegy Ellipta, Breo Ellipta$448$16,16728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →